Summary The effects of flavone acetic acid (FAA) on the coagulation properties of plasma from tumourbearing and non-tumour-bearing mice have been investigated. The study was carried out primarily on CBA mice and the CaNT tumour, although substantiating data are included for two other tumours grown in the WH strain. FAA was injected at a range of single doses up to a maximum of 300 mg kg-', and clotting properties of the plasma were measured in vitro at various times after FAA administration. Platelet numbers and the concentration of fibrin degradation products (FDP) in the plasma were also determined. Following a dose of 300 mg kg', the clotting times were significantly reduced at 15-30 min in both tumour-bearing and non-tumour-bearing mice of both strains. Detailed studies on coagulation in the CBA strain (± CaNT tumour) indicate that in tumour-bearing animals the initial decrease in clotting time is followed 4-6 h later by an increase in clotting time, thrombin time and FDP levels. Platelet counts of tumour-bearing mice also decreased signficantly over this period. Similar experiments in non-tumour-bearing mice did not show these late effects. All the data from the coagulation tests on mice with CaNT tumours are consistent with the hypothesis that intravascular coagulation occurs following treatment with FAA, and that vascular occlusion in tumours, as a results of FAA-induced coagulopathy, may contribute to tumour regression.
Flavone acetic acid (FAA) is a synthetic flavonoid which is currently undergoing clinical trials. Its clinical use is based on its observed antitumour effects against a variety of solid mouse tumours (Corbett et al., 1986; Bibby et al., 1987; Finlay et al., 1988) . However, unlike most antitumour agents it is relatively non-toxic to cells in vitro (Bibby et al., 1987; Capolongo et al., 1987; Schroyens et al., 1987) , and consequently its mechanism of action is uncertain. Several aspects of the observed effects in tumours suggest that its toxicity in vivo may be mediated via damage to the vasculature: (1) the drug induces rapid cell death and tumour necrosis within 4-6 h (Smith et al., 1987; Finlay et al., 1988) ; (2) it is most effective against solid tumours grown subcutaneously, showing significantly less activity against lymphomas and leukaemias and tumours growing as ascites (Corbett et al., 1986; Bibby et al., 1987) ; (3) it is more effective against large established tumours than against newly implanted tumour cells (Double et al., 1986; Finlay et al., 1988) ; (4) it causes a rapid shutdown of tumour vasculature (Bibby et al., 1989; Hill et al., 1989; Zwi et al., 1989) .
Many of the features of FAA treated tumours have also been observed in mice treated with tumour necrosis factor (TNF) (Old, 1985) , which suggests that common elements in their mechanism of action may exist. Since TNF has been shown to change the coagulant properties of endothelial cells grown in vitro and to cause fibrin deposition in murine tumours (Nawroth et al., 1988) , we have investigated the role of coagulation in the response of three murine tumours to FAA. In this paper, we report the effects of single doses of FAA on the clotting characteristics of plasma from tumourbearing and control mice.
Materials and methods
Mice and tumours Experiments were carried out using three routinely passaged tumours in use at the Gray Laboratory: CaNT, a moderately differentiated adenocarcinoma, grown in CBA/HtBSVS mice, and SaFA and FibT, two poorly differentiated fibrosarcomas, grown in WHT/GyBSVS mice. All experiments were done using male mice. Tumours were implanted subcutaneously on the back as has been described previously Figure 1 shows the platelet counts obtained from untreated mice and from mice given a single dose of 300 mg kg-' FAA 15-360 min earlier. Data are for non-tumour bearing CBA mice and for mice with CaNT tumours with an average measured diameter of 10-12 mm. In untreated mice, the platelet counts from tumour-bearing mice were significantly lower than those from CBA controls (P<0.01). Following administration of FAA, the platelet counts from CBA mice show only a small decrease over 6 h. By comparison, the platelet counts from mice with CaNT tumours fall rapidly from 30 min after injection of FAA, so that by 4 h after injection the platelet counts have dropped by approximately 60%, indicating a significant FAA-induced thrombocytopenia.
The dose dependence of the effects of FAA on platelet counts in tumour-bearing mice are shown in Figure 2 . Data are from the mice with 10-12 mm diameter CaNT tumours. Blood samples were obtained 30 min and 360 min after injection. None of the FAA doses had an effect on the platelet counts of samples collected 30 min after injection. However, there is a dose-dependent decrease in the platelet counts of mice treated 360 min earlier.
Clotting times
The clotting times of tumour-bearing and non-tumourbearing CBA mice following a dose of 300 mg kg-' FAA are shown in Figure 3 . Data are from 15 min to 6 h after injection. For mice given no FAA (i.e. at time 0), the samples of plasma from mice with CaNT tumours had longer clotting times than those from mice with no tumour (67 ± 5 s vs 53 ± 4s; P<0.0 1). Following FAA administration, the clotting times of plasma from both groups decreased within 30 min of injection. In non-tumour mice, the clotting times returned to normal within 60 min and were then stable over the observation period. By comparison, the clotting times of mice with 10-12 mm tumours remained depressed for approximately 4 h after FAA injection, after which time an increase was observed.
Similar changes in clotting time were observed following a dose of 300 mg kg-' FAA in the WH mouse strain and in WH mice bearing FibT and SaFA tumours. As with the CBA strain, the presence of a tumour also led to an increase in the clotting times of untreated mice. The data from both strains and all three types of tumour are summarised in Table I . For each group, both the absolute values (in seconds) and the percentage change in clotting time are shown at 15-30 min and 4-6 h after injection.
Prothrombin times
The prothrombin times as a function of time after administration of 300 mg kg-' FAA are also shown in Figure 3 . Data are again from non-tumour-bearing CBA mice and mice with 10-12 mm CaNT tumours. The prothrombin times were constant in both groups for at least 6 h after injection of FAA.
The importance of thromboplastin on the differences between the clotting and prothrombin times is shown in Figure 4 . Data in Figure 4a are from non-tumour bearing However, these differences disappeared as the thromboplastin concentration was increased. Both sets of data emphasise the significant alteration in the coagulation potential of both tumour-bearing and. control mice induced by FAA. Experiments were also carried out to determine whether FAA acts directly on coagulation factors in the blood. Blood was collected as described previously, and samples of whole blood or plasma incubated in vitro for 30 min at 37°C with mg ml-' FAA. The samples were then processed as usual and the clotting and prothrombin times measured. The results showed that FAA added directly to blood or plasma does not cause a decrease in clotting time similar to that observed in vivo (data not shown).
Thrombin times
The thrombin times of both tumour bearing and non-tumour bearing CBAs are plotted as a function of time after 300 mg kg-' FAA in Figure 5 . For non-tumour bearing animals, the thrombin times are constant for at least 6 h. By comparison, although the thrombin times of tumour bearing animals are constant for the first 4 h following FAA, a significant increase in thrombin times is observed at 6 h (from 18±0.8 at 4h to 30± 1.7 at 6h, P<0.05). FDP assay FDP levels were measured in samples obtained I or 6 h after 300 mg kg-' FAA. Data from both non-tumour-bearing mice and from mice with 10-12 mm tumours are plotted in Figure  6 . In tumour-bearing mice, there was a dose-dependent increase in FDP levels I and 6 h after injection (Figure 6a ). By comparison, in non-tumour bearing mice there was no significant change in FDP levels at any of the doses tested. These results indicate a marked increase in fibrinolysis in tumour-bearing mice treated with FAA even at early times after treatment. The results of the clotting time (CT) assays indicate that the coagulation pathway was activated in all mice after administration of FAA, producing an early drop (within 1 h) in CT. The absolute drop in CT was generally greater in tumour-bearing mice, although the difference between tumour-bearing and control mice did not achieve statistical significance in our series of experiments (see Table I ). FAA did not influence the results obtained with the other coagulation assays during this early phase. The mechanism by which FAA initiates this early change in clotting potential in mice has not been determined. However, we were unable to induce a decrease in clotting time by adding FAA to citrated mouse Time after FAA (min) plasma in vitro, which suggests that either the drug must be converted to an active form in vivo or that the changes in 5 Thrombin times of mice 1 v360lmi after treatment coagulation are mediated via a cellular response.
s. * CBAs + 10-12 mm CaNT tumours; m CBAs. Data During the period 4-6 h after injection of FAA, significant are shown ± I s.d. differences in the clotting properties of non-tumour and tumour-bearing mice were observed. Clotting times (CT) in tumour-bearing mice rose well above control values in two of the three tumour systems tested (Table I ). There was also a significant depletion of platelets and fibrinogen and an increase in the levels of fibrin degradation products (FDP) in the plasma. All these factors provide strong indirect evidence that intravascular coagulation had occured in tumourbearing mice treated with FAA. The severity of these effects was dependent upon the dose of FAA. We measured increases in the levels of FDP from 1 h after FAA administration, indicating that some degree of clot formation and dissolution had occurred by that time. nt decrease in tumour blood flow in experimental However, comparative data from non-tumour-bearers are not s (Bibby et al., 1989; Hill et al., 1989; Zwi et al., available and it is impossible to know whether these effects Further, Zwi et al. (1989) have produced in vivo/in are analogous to our observations in mice. The induction of mour-cell survival data which indicate that cell death coagulation specifically within the tumour has been proposed ie first 4 h post-FAA treatment may be due to as the mechanism by which endotoxin (Gratia & Linz, 1931 ) ia resulting from the reduced blood flow. In this and TNF (Parr et al., 1973; Nawroth et al., 1988) exert their paper we have sought to determine if the FAA antitumour action. Our own data also indicate that FAA decrease in blood flow in tumours is due to alteraproduces changes in coagulation, and in terms of the coagulation, and have shown: (a) that FAA causes sequence of events taking place within 6 h of treatment, the d procoagulant activity at short times after administ-effects of FAA in tumour-bearing mice fulfil many of the (b) that in tumour-bearing mice, this increased pro-descriptive criteria of disseminated intravascular coagulation (DIC) (Brozovic, 1987) . Although the results of our experiments do not demonstrate a causal relationship between the coagulopathy associated with single doses of FAA and tumour regression, our data do indicate that FAA produces changes in coagulation which in tumour-bearing mice leads to a coagulopathy. We suggest that thrombus formation in the tumour may cause the observed drop in tumour blood flow following FAA administration, which then leads to ischaemic cell death (Zwi et al., 1989) . In order to ascertain whether a causal relationship does exist between the observed changes in coagulation and tumour regression, we are currently examining the effects of antithrombotic agents administered before FAA.
